Moreover, positive results from the treatment of human U87 glioma-bearing murine models with MSCs secreting IFN-β indicated that MSCs can migrate into brain tissue following local or systemic delivery, allowing for the treatment of human glioma (64). This evidence concerns the gene IFNB1 and glioma.